# An OS to Evaluate Effectiveness and Safety of Fixed-dose Combinations of FMS/AML or FMS/AML/HCTZ

> **NCT05413057** · — · RECRUITING · sponsor: **Boryung Pharmaceutical Co., Ltd** · enrollment: 20000 (estimated)

## Conditions studied

- Hypertension,Essential

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05413057
- **Lead sponsor:** Boryung Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2022-06-23
- **Primary completion:** 2026-06
- **Final completion:** 2026-06
- **Target enrollment:** 20000 (ESTIMATED)
- **Last updated:** 2025-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05413057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05413057, "An OS to Evaluate Effectiveness and Safety of Fixed-dose Combinations of FMS/AML or FMS/AML/HCTZ". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05413057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*